The purpose of this study is to determine the safety and effectiveness of anakinra in patients with Polyarticular-Course Juvenile Rheumatoid Arthritis, a form of rheumatoid arthritis affecting children.

Condition	Treatment or Intervention	Phase
Juvenile Chronic Arthritis	Drug: Anakinra	Phase II Phase III

Ages Eligible for Study:  2 Years   -   17 Years,  Genders Eligible for Study:  Both

Criteria

• Male or female age 2-17 yrs inclusive
• Minimum weight 10 KG
• Diagnosis of Chronic Arthritis

Arkansas
      Research Center, Little Rock,  Arkansas,  United States
California
      Research Center, Los Angeles,  California,  United States
New Jersey
      Research Center, Hackensack,  New Jersey,  United States
New York
      Research Center, New Hyde Park,  New York,  United States
Ohio
      Research Center, Cincinnati,  Ohio,  United States
Oklahoma
      Research Center, Tulsa,  Oklahoma,  United States
Texas
      Research Center, Dallas,  Texas,  United States
Wisconsin
      Research Center, Milwaukee,  Wisconsin,  United States

Study ID Numbers:  990758-990779
Record last reviewed:  August 2003
Last Updated:  October 13, 2004
Record first received:  May 17, 2002
ClinicalTrials.gov Identifier:  NCT00037648
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08